MA50613A - Molécules de liaison spécifique à l'hpv - Google Patents

Molécules de liaison spécifique à l'hpv

Info

Publication number
MA50613A
MA50613A MA050613A MA50613A MA50613A MA 50613 A MA50613 A MA 50613A MA 050613 A MA050613 A MA 050613A MA 50613 A MA50613 A MA 50613A MA 50613 A MA50613 A MA 50613A
Authority
MA
Morocco
Prior art keywords
hpv
specific binding
binding molecules
molecules
specific
Prior art date
Application number
MA050613A
Other languages
English (en)
Inventor
Brian Belmont
Christopher Borges
Cameron Brandt
Stephen Michael Burleigh
Alexandra Croft
Stephen Jacob Goldfless
David Jeffrey Huss
Yue Jiang
Timothy G Johnstone
David Koppstein
Hieu Nguyen
Christopher Heath Nye
Haley Peper
Blythe D Sather
James Sissons
Sonia Timberlake
Dean Y Toy
Queenie Vong
Gordon Grant Welstead
Original Assignee
Editas Medicine Inc
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc, Juno Therapeutics Inc filed Critical Editas Medicine Inc
Publication of MA50613A publication Critical patent/MA50613A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
MA050613A 2017-10-03 2018-09-28 Molécules de liaison spécifique à l'hpv MA50613A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567750P 2017-10-03 2017-10-03
US201762597411P 2017-12-11 2017-12-11
US201862653529P 2018-04-05 2018-04-05

Publications (1)

Publication Number Publication Date
MA50613A true MA50613A (fr) 2020-08-12

Family

ID=63963486

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050613A MA50613A (fr) 2017-10-03 2018-09-28 Molécules de liaison spécifique à l'hpv

Country Status (13)

Country Link
US (1) US11952408B2 (fr)
EP (2) EP3692063A1 (fr)
JP (2) JP2020537515A (fr)
KR (1) KR20200104284A (fr)
CN (1) CN111954679A (fr)
AU (1) AU2018345539A1 (fr)
BR (1) BR112020006643A2 (fr)
CA (1) CA3080546A1 (fr)
IL (1) IL273631A (fr)
MA (1) MA50613A (fr)
MX (1) MX2020003536A (fr)
SG (1) SG11202002728VA (fr)
WO (1) WO2019070541A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CA3116132A1 (fr) 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions et procedes d'immunotherapie
CA3136737A1 (fr) * 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cellules exprimant un recepteur recombinant a base d'un locus modifie du tgfbr2, et polynucleotides et methodes associes
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
EP3786178A1 (fr) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Constructions tcr spécifiques pour antigènes dérivés du virus d'epstein-barr (ebv)
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的t细胞受体及其编码序列
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术(广东)有限公司 一种识别hpv的t细胞受体
EP4125949A4 (fr) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research Compositions et méthodes de ciblage de cellules infectées par le vhp
WO2021195503A1 (fr) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. Récepteurs de lymphocytes t
JP7645500B2 (ja) * 2020-05-07 2025-03-14 ブリスター イムノテック リミテッド 改善されたt細胞受容体共刺激分子キメラ
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CN113801217B (zh) * 2020-06-17 2025-12-23 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的高亲和力t细胞受体
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法
WO2022060904A1 (fr) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions et procédés pour l'expression de récepteurs de lymphocytes t avec cd40l régulé par petites molécules dans les lymphocytes t
IL301255A (en) * 2020-10-09 2023-05-01 UCB Biopharma SRL Nucleic acid structures, viral vectors and viral particles
WO2022093694A1 (fr) * 2020-10-26 2022-05-05 A2 Biotherapeutics, Inc. Polypeptides ciblant des complexes peptide hpv-cmh et leurs méthodes d'utilisation
EP4240378A4 (fr) * 2020-11-05 2025-02-12 Board of Regents, The University of Texas System Récepteurs de lymphocytes t ciblant des antigènes egfr et procédés d'utilisation
WO2022099032A1 (fr) * 2020-11-06 2022-05-12 Bioventures, Llc Lymphocytes t et protéine bifonctionnelle contre le papillomavirus humain
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的tcr
WO2022133592A1 (fr) * 2020-12-21 2022-06-30 Zymeworks Inc. Constructions tcr stabilisées et procédé d'utilisation
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
WO2022233956A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant de manière spécifique à prame
MX2023014356A (es) * 2021-06-02 2024-02-15 Metagenomi Inc Sistemas crispr de clase ii, tipo v.
CN115677846A (zh) * 2021-07-27 2023-02-03 香雪生命科学技术(广东)有限公司 针对抗原ssx2的高亲和力t细胞受体
WO2023036169A1 (fr) * 2021-09-07 2023-03-16 Corregene Biotechnology Co., Ltd. Protéines de liaison à l'antigène et leurs utilisations
CN115819555A (zh) * 2021-09-17 2023-03-21 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力tcr
WO2023050063A1 (fr) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 Tcr reconnaissant hla-a*02:01/e629-38, et son utilisation
CN113912701B (zh) * 2021-10-14 2024-07-19 深圳大学总医院 Tcr及其在诊断/治疗中的应用
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
WO2023081900A1 (fr) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
WO2023086477A2 (fr) * 2021-11-10 2023-05-19 Tscan Therapeutics, Inc. Protéines de liaison reconnaissant l'antigène hpv16 e7 et leurs utilisations
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术(广东)有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
WO2023196884A1 (fr) * 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Dosage pour la détection du papillomavirus humain (vph) de type 16 (hpv-16)
CN119365484A (zh) * 2022-04-28 2025-01-24 Cue生物制药股份有限公司 修饰的细胞毒性t细胞及其使用方法
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
CN116589557B (zh) * 2023-03-15 2024-04-02 北京大学人民医院 一种肿瘤新生抗原特异性tcr及其应用
WO2025137646A1 (fr) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Méthodes d'édition de gènes et compositions pour le traitement de la fibrose kystique
WO2025226774A1 (fr) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. Récepteurs de lymphocytes t ciblant l'antigène mineur d'histocompatibilité acc-1
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026025092A1 (fr) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Promoteurs synthétiques pour expression de lymphocytes t
WO2026123001A2 (fr) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Thérapie par cellules modifiées à loci spécifiques de lignée et procédés de production et d'utilisation associés
WO2026136848A2 (fr) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Récepteurs car ciblant cd70, cellules modifiées les comprenant et procédés associés

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
CA2196419C (fr) 1994-08-20 2007-08-21 Yen Choo Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2305630C (fr) 1997-10-02 2012-11-06 Sunol Molecular Corporation Proteines solubles du recepteur des lymphocytes t a chaine unique
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
CA2307166A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
CA2313641A1 (fr) 1997-12-12 1999-06-24 Digene Corporation Milieu de prelevement universel
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO2000014257A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
WO2002077012A2 (fr) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptides immunoreactifs du papillomavirus humain
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
EP1498491A4 (fr) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia
CA2481920A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (fr) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Procede de production de composition anticorps
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
EP1708745B1 (fr) 2003-12-23 2012-04-18 Arbor Vita Corporation Anticorps pour des souches oncogenes du hpv et leurs methodes d'utilisation
EP1791865B1 (fr) 2004-06-29 2010-07-28 Immunocore Ltd. Cellules exprimant une cellule t recepteur modifiee
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
EP1809669A2 (fr) 2004-10-01 2007-07-25 Avidex Ltd Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Hla−a24拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2468763B1 (fr) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Épitopes HPV ciblés par des lymphocytes T infiltrant des malignités cervicales à utiliser dans des vaccins
US20090117140A1 (en) 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
EP2520643B8 (fr) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Systèmes de traitement d'échantillons et procédés
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
KR20090103571A (ko) 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
KR20090125629A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물
KR20090125628A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ, インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
CN102498217A (zh) 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
WO2011044186A1 (fr) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Récepteurs de lymphocytes t à chaîne unique humains
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
DK2993183T3 (da) 2010-02-16 2020-03-30 Oesterreichische Akademie Der Wss Anti-hpv e7-antistoffer
US9228007B1 (en) 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
KR101415554B1 (ko) 2010-09-13 2014-07-04 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
EP3561073A1 (fr) 2010-10-08 2019-10-30 President and Fellows of Harvard College Séquençage immunitaire à haut rendement
US9902950B2 (en) 2010-10-08 2018-02-27 President And Fellows Of Harvard College High-throughput single cell barcoding
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (fr) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Méthodes et compositions pour une immunothérapie cellulaire
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2567972A1 (fr) 2011-09-12 2013-03-13 Adriacell S.p.A. Anticorps contre la protéine E7 du virus du papillome humain
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
WO2013071154A1 (fr) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
WO2013074916A1 (fr) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CA2871524C (fr) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Procedes et compositions pour l'integration mediee par nuclease de transgenes
CA3132353A1 (fr) 2012-05-08 2013-11-14 The Johns Hopkins University Methodes et compositions pour la perfusion de populations choisies de lymphocytes allogeniques a prise de greffe transitoire pour traiter le cancer
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2997146A4 (fr) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Procédés et compositions pour le traitement d'une maladie génétique
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
CN105452448B (zh) 2013-07-15 2020-07-28 美国卫生和人力服务部 制备抗人乳头瘤病毒抗原的t细胞的方法
CN103342738B (zh) 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
JP5921042B2 (ja) 2013-07-30 2016-05-24 シャープ株式会社 光拡散部材の製造方法
WO2015018943A2 (fr) 2013-08-08 2015-02-12 Institut Pasteur Corrélation entre une activité pathologique et des expansions clonales de cellules t cd8+ spécifiques du virus du papillome humain 16 chez des patients souffrant de lichens plans oraux érosifs sévères
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
US20160250258A1 (en) 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
EP3172048A4 (fr) 2014-07-11 2018-04-18 Intel Corporation Dispositifs électroniques pliables et étirables et procédés associés
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
RU2017102769A (ru) 2014-07-29 2018-08-28 Пфайзер Инк. EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
EP3177314B1 (fr) 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center Immunothérapie par cellules t spécifiques de la wt-1
US10590483B2 (en) 2014-09-15 2020-03-17 Abvitro Llc High-throughput nucleotide library sequencing
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
JP2018516879A (ja) 2015-05-08 2018-06-28 ユーリカ セラピューティックス, インコーポレイテッド Hpv16−e7ペプチド/mhc複合体を標的化する構築物およびその使用
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA2991301A1 (fr) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Procedes d'administration et compositions pour genie genomique medie par nuclease
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
EP3156067A1 (fr) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin Récepteurs de lymphocytes t hpv à avidité élevée
WO2017070429A1 (fr) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Procédés consistant à éditer des polynucléotides codant pour un récepteur de lymphocytes t
JP6777841B2 (ja) 2015-10-23 2020-10-28 国立大学法人金沢大学 細胞傷害性t細胞の作製方法
WO2017093969A1 (fr) 2015-12-04 2017-06-08 Novartis Ag Compositions et procédés d'immuno-oncologie
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
EP3452499A2 (fr) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Cellules génétiquement modifiées et leurs procédés de fabrication
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
US9642906B2 (en) 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
WO2018073393A2 (fr) 2016-10-19 2018-04-26 Cellectis Cellules allogéniques modifiées par une nucléase d'effecteur tal (talen) appropriées pour une thérapie
WO2018097257A1 (fr) * 2016-11-28 2018-05-31 国立大学法人大阪大学 Procédé d'édition du génome
CN118460529A (zh) * 2016-12-20 2024-08-09 百时美施贵宝公司 提高细胞基因组中同源定向修复(hdr)效率的方法
CN110869046B (zh) 2017-03-31 2025-02-25 塞勒克提斯公司 通用型抗cd22嵌合抗原受体工程化的免疫细胞
JP7170666B2 (ja) 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ,インク. 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
EP4775669A2 (fr) 2017-06-30 2026-07-15 Precision Biosciences, Inc. Lymphocytes t génétiquement modifiés comprenant un intron modifié dans le gène alpha du récepteur des lymphocytes t
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法

Also Published As

Publication number Publication date
KR20200104284A (ko) 2020-09-03
AU2018345539A1 (en) 2020-04-16
JP2023099142A (ja) 2023-07-11
WO2019070541A1 (fr) 2019-04-11
JP2020537515A (ja) 2020-12-24
EP4215543A3 (fr) 2023-10-11
CN111954679A (zh) 2020-11-17
SG11202002728VA (en) 2020-04-29
RU2020115148A (ru) 2021-11-09
MX2020003536A (es) 2020-09-14
CA3080546A1 (fr) 2019-04-11
US20210284709A1 (en) 2021-09-16
IL273631A (en) 2020-05-31
EP3692063A1 (fr) 2020-08-12
BR112020006643A2 (pt) 2020-09-24
EP4215543A2 (fr) 2023-07-26
US11952408B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
IL273631A (en) Special hpv molecules bind
EP3331564A4 (fr) Constructions de liaison d'antigène se liant à des molécules cibles
EP3402519A4 (fr) Constructions de liaison à l'antigène immunomodulateur multispécifique
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
EP3655432A4 (fr) Protéines de liaison 1
EP3717505A4 (fr) Protéines de liaison à l'adn modifiées
EP3329237A4 (fr) Mécanisme statiquement équilibré à l'aide de cylindres de halbach
MA44505A (fr) Anneaux de compression extensibles pour liaison anastomotique améliorée de tissus
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3408400A4 (fr) Protéines de liaison à l'antigène se liant à pd-l1
EP4013792A4 (fr) Molécules de liaison multimériques immunostimulatrices
DK3645570T3 (da) VISTA-antigenbindende molekyler
EP3319936A4 (fr) Lieux de pontage pour la conjugaison des molécules de liaison cellulaire
MA41414A (fr) Protéines de liaison agonistes d' icos
EP2850103A4 (fr) Protéines de liaison à l'antigène st2
GB201811403D0 (en) Antibody molecules
EP3335124A4 (fr) Fichiers de registre pour compression de paquets e/s
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
EP3426298A4 (fr) Molécules de liaison à l'ilt7 et leurs méthodes d'utilisation
EP3641847A4 (fr) Robinet d'arrêt
EP3781204A4 (fr) Molécules de liaison
EP3688185A4 (fr) Dosage de liaison d'affinité numérique
EP3990428A4 (fr) Nouvelles molécules
EP3774922A4 (fr) Molécules de liaison impliquant des cellules
EP3941947A4 (fr) Molécules de liaison anti-her2